Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.56 |
| ▸ | NOS3 | P29474 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28571320 | 0.83 | NOS2 (0.52) | NOS2NOS3LMNALIMK1POLB | |
| SCHEMBL21603386 | 0.83 | NOS2 (0.52) | NOS2NOS3LMNALIMK1POLB | |
| SCHEMBL28562569 | 0.83 | NOS2 (0.52) | NOS2NOS3LMNALIMK1POLB | |
| SCHEMBL10204659 | 0.77 | NOS2 (0.48) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL22096897 | 0.77 | NOS3 (0.34) | NOS2NOS3NOS1MEN1KMT2A | |
| SCHEMBL993753 | 0.76 | CCR1 (0.38) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL21719115 | 0.74 | HPGD (0.41) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL11955166 | 0.74 | CCR1 (0.37) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL22096913 | 0.74 | GABRA1 (0.42) | NOS2NOS3LMNALIMK1POLB | |
| SCHEMBL21718934 | 0.74 | CCR1 (0.37) | NOS2NOS3CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889561-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | NOS2 1227/4885NOS3 887/4885LMNA 3475/4885 |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | NOS2 852/4885NOS3 649/4885LMNA 2799/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | NOS2 1227/4885NOS3 887/4885LMNA 3475/4885 |
| US-10889561-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | NOS2 852/4885NOS3 649/4885LMNA 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.